Currently out of the existing stock ratings of Robert Burns, 409 are a BUY (87.96%), 56 are a HOLD (12.04%).

Robert Burns

Work Performance Price Targets & Ratings Chart

Analyst Robert Burns, carries an average stock price target met ratio of 23.89% that have a potential upside of 41.41% achieved within 111 days. Previously, Robert Burns worked at HC WAINWRIGHT.

Robert Burns’s has documented 958 price targets and ratings displayed on 47 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on NRIX, Nurix Therapeutics at 19-Oct-2025.

Wall Street Analyst Robert Burns

Analyst best performing recommendations are on PRLD (PRELUDE THERAPEUTICS ).
The best stock recommendation documented was for PRLD (PRELUDE THERAPEUTICS ) at 9/10/2024. The price target of $5 was fulfilled within 1 day with a profit of $0.38 (7.06%) receiving and performance score of 70.63.

Average potential price target upside

of $32.03 (50.09%) on IKNA (IKENA ONCOLOGY).
of $29.09 (122.45%) on SWTX (SPRINGWORKS THERAPEUTICS).
of $19.83 (23.5%) on TPTX (TURNING POINT THERAPEUTICS).

AADI Aadi Bioscience BNTX BioNTech SE CRBU Caribou Biosciences CTMX CytomX Therapeutics FATE Fate Therapeutics IGMS IGM Biosciences MGNX MacroGenics NRIX Nurix Therapeutics NUVB Nuvation Bio ORIC Oric Pharmaceuticals RLAY Relay Therapeutics RPTX Repare Therapeutics RVMD Revolution Medicines ADCT ADC Therapeutics SA IKNA Ikena Oncology KRON Kronos Bio NCNA NuCana PLC PRTG Portage Biotech TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics ZYME Zymeworks Common Stock SWTX SpringWorks Therapeutics NLTX Neoleukin Therapeutics PRLD Prelude Therapeutics YMAB Y mAbs Therapeutics ATRA Atara Biotherapeutics GTBP GT Biopharma KNTE Kinnate Biopharma OMGA Omega Therapeutics PMVP Pmv Pharmaceuticals REPL Replimune Group TNGX Tango Therapeutics ALLO Allogene Therapeutics BDTX Black Diamond Therapeutics COGT Cogent Biosciences VIRX Viracta Therapeutics AUTL Autolus Therapeutics Ltd FMTX Forma Therapeutics Holdings EXEL Exelixis AVBP ArriVent BioPharma, Common Stock BCAX Bicara Therapeutics Common Stock CRGX CARGO Therapeutics, Common Stock ELVN Enliven Therapeutics OKUR OnKure Therapeutics CGEM Cullinan Oncology LLC CRDF Cardiff Oncology KPTI Karyopharm Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joseph Catanzaro